Temocillin Versus Carbapenems for Urinary Tract Infection Due to ESBL-producing Enterobacteriaceae
Temocillin Versus Carbapenems for Urinary Tract Infection Due to ESBL-producing Enterobacteriaceae
To assess the efficacy of temocillin compared to carbapenems for the management of ESBL-E
 UTI.
Adults with a definite diagnosis of ESBL-E UTI between January-2015 and October-2019 were
 enrolled in a multicenter retrospective case-control study. Cases were treated with
 temocillin ≥50% of the effective antibiotic therapy duration. Control exclusively received
 carbapenem over the effective antibiotic therapy duration.
Inclusion Criteria:

 -  Adults

 -  Diagnosis of UTI defined by at least two of the following symptoms :chills,temperature
 >38°C (fever), flank or pelvic pain, nausea or vomiting, dysuria, urinary frequency,
 or urinary urgency, costovertebral angle tenderness on physical examination

 -  Positive urine culture with ≥ 103 CFU/mL of a single strain of ESBL-E

 -  Confirmed ESBL-producing enterobacteriaceae (ESBL-E) susceptible to carbapenems

 Exclusion Criteria:

 -  Multibacterial infection

 -  Opposition to data collection according to GDPR